Nyxoah (NYXH) Stock Overview
A medical technology company, focuses on the development and commercialization of solutions to treat obstructive sleep apnea. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
NYXH Community Fair Values
Create NarrativeSee what 11 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Nyxoah SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €1.49 |
| 52 Week High | €8.87 |
| 52 Week Low | €1.26 |
| Beta | 0.96 |
| 1 Month Change | 6.12% |
| 3 Month Change | -46.71% |
| 1 Year Change | -77.56% |
| 3 Year Change | -77.86% |
| 5 Year Change | -94.54% |
| Change since IPO | -92.35% |
Recent News & Updates
Narrative Update • Jul 07
NYXH: Capital Raise Will Support Execution Of 2026 Revenue Guidance
Analysts have cut the Nyxoah fair value estimate from €7.37 to €5.80 after recent price target reductions, citing updated models that factor in the latest capital raise, quarterly results, and balance sheet considerations. Analyst Commentary Recent Street research on Nyxoah highlights a mix of optimism around product uptake and caution around funding needs and execution risk, which feeds directly into the reduced fair value estimate.Narrative Update • Jun 22
NYXH: Capital Raise And U.S. Revenue Progress Will Drive 2026 Momentum
Analysts have trimmed their average Nyxoah price target by about €1.63, reflecting recent cuts from firms that updated their models for the company’s capital raise and balance sheet needs, even as they highlight progress in the Genio launch and U.S. net revenue trends. Analyst Commentary Recent research on Nyxoah highlights a mix of cautious valuation resets and ongoing confidence in the company’s product rollout and revenue trajectory, especially around the Genio launch and U.S. net revenue trends.Recent updates
Narrative Update • Jul 07
NYXH: Capital Raise Will Support Execution Of 2026 Revenue Guidance
Analysts have cut the Nyxoah fair value estimate from €7.37 to €5.80 after recent price target reductions, citing updated models that factor in the latest capital raise, quarterly results, and balance sheet considerations. Analyst Commentary Recent Street research on Nyxoah highlights a mix of optimism around product uptake and caution around funding needs and execution risk, which feeds directly into the reduced fair value estimate.Narrative Update • Jun 22
NYXH: Capital Raise And U.S. Revenue Progress Will Drive 2026 Momentum
Analysts have trimmed their average Nyxoah price target by about €1.63, reflecting recent cuts from firms that updated their models for the company’s capital raise and balance sheet needs, even as they highlight progress in the Genio launch and U.S. net revenue trends. Analyst Commentary Recent research on Nyxoah highlights a mix of cautious valuation resets and ongoing confidence in the company’s product rollout and revenue trajectory, especially around the Genio launch and U.S. net revenue trends.
Narrative Update • Jun 05
NYXH: Future Reimbursement Clarity Will Support Funding Visibility And Long Term Upside
Nyxoah's analyst price target has been reduced by €2 to €7, as analysts factor in recent target cuts across firms alongside steady Genio launch progress. U.S. net revenue is described as up 25% quarter over quarter, and recent research has highlighted balance sheet funding needs.Narrative Update • May 19
NYXH: Future CMS Procedure Codes Will Support Reimbursement Clarity And Upside Potential
Nyxoah's updated analyst price target has shifted from €9 to €7, as analysts factor in recent target cuts across several firms while still pointing to progress in the Genio launch, particularly U.S. net revenue that was up 25% quarter over quarter and aligned with company expectations, alongside a view that the balance sheet may need additional support. Analyst Commentary Bullish analysts are acknowledging the lower price targets while still pointing to concrete execution milestones, especially around the Genio launch and U.S. commercialization.Analysis Article • May 15
Analysts Are Upgrading Nyxoah SA (EBR:NYXH) After Its Latest Results
Shareholders might have noticed that Nyxoah SA ( EBR:NYXH ) filed its first-quarter result this time last week. The...Narrative Update • May 04
NYXH: CMS Code Clarity And 2026 Revenue Ramp Will Drive Momentum
Nyxoah's analyst price targets have been trimmed by around €0.15 overall as analysts factor in a slightly higher discount rate, a lower profit margin assumption and a higher future P/E, even as longer term revenue expectations remain broadly unchanged. Analyst Commentary Recent Street research on Nyxoah has focused on refinement of price targets and on reimbursement developments that could influence the company’s long term growth and valuation profile.
Narrative Update • Apr 20
NYXH: Future Reimbursement Codes And Manufacturing Expansion Will Support Upside
Analysts have trimmed their average price target on Nyxoah by about €0.50 as they factor in slightly higher discount rates and updated P/E assumptions, while still pointing to supportive sector developments such as the planned addition of dedicated reimbursement codes for the company’s procedures from 2026. Analyst Commentary Recent research has leaned more cautious on Nyxoah, with several bearish analysts trimming their price targets in close succession.Narrative Update • Apr 06
NYXH: Future Reimbursement Clarity And Execution On U.S. Rollout Will Drive Upside
Analysts have trimmed their Nyxoah price targets, with the fair value estimate moving from €5.00 to €4.00. This reflects updated views on discount rates, growth expectations and profitability, even as recent CMS coding news is seen as directionally positive for the company's procedures.Narrative Update • Mar 23
NYXH: Reimbursement Code Clarity Will Drive Future Momentum
Narrative Update Nyxoah's consensus analyst price target has been trimmed by about €0.33, as analysts factor in updated fair value assumptions, a slightly higher discount rate and a higher future P/E, alongside recent reimbursement related news and incremental adjustments from Stifel. Analyst Commentary Recent research updates focus on adjustments to Nyxoah's valuation assumptions and the impact of upcoming reimbursement changes tied to new procedure codes.Narrative Update • Mar 08
NYXH: CMS Procedure Codes And Reimbursement Clarity Will Support Long Term Upside
Analysts now keep their Nyxoah fair value target steady at €13.00, noting that new CMS procedure codes are a supportive step for reimbursement clarity while modestly adjusting assumptions around discount rate, revenue growth and future P/E. Analyst Commentary Recent Street research around hypoglossal nerve stimulation is giving bullish analysts more confidence that Nyxoah’s reimbursement path is becoming clearer, which they see as an important input to fair value for the shares.Narrative Update • Feb 22
NYXH: Manufacturing Expansion And European Rollout Will Drive Future Momentum
Analysts have trimmed their Nyxoah price target by €0.50, reflecting updated assumptions around fair value, discount rate, growth expectations, profit margins and future P/E multiples discussed in recent research. Analyst Commentary Recent research around Nyxoah links the lower price target to updated views on fair value, discount rate, growth expectations, profit margins and future P/E multiples.Narrative Update • Feb 07
NYXH: Early U.S. Reimbursement Progress Will Support Long Term Upside Potential
Narrative Update Analysts have modestly trimmed their price targets on Nyxoah, with recent cuts including a move to $9 and a $1 reduction elsewhere, reflecting updated views on U.S. Genio launch progress, reimbursement approval complexity, and near term revenue guidance that is viewed as appropriately calibrated. Analyst Commentary Bullish analysts are still highlighting constructive elements in the Nyxoah story, even as they recalibrate price targets to reflect the current pace of the U.S. Genio rollout and reimbursement progress.Narrative Update • Jan 24
NYXH: U.S. Reimbursement Progress Will Underpin Long Term Upside Potential
Analysts have trimmed their price targets on Nyxoah, with one key target moving from €12 to €9, citing in-line Q3 revenue of €2.0m, early U.S. Genio launch progress including 15 implants and 35 VAC approvals, and Q4 revenue guidance of €3.4m to €3.6m, which they view as appropriately set. Analyst Commentary Bullish analysts are framing the lower €9 price target as a recalibration rather than a negative call, pointing out that the core thesis on Nyxoah remains tied to execution on the U.S. Genio launch and delivery against near term revenue guidance.Narrative Update • Jan 09
NYXH: Execution On U.S. Reimbursement Approvals Will Drive Future Upside Potential
Nyxoah's updated analyst price target has shifted to reflect a €5.00 fair value, with analysts pointing to a higher discount rate, very large forecast revenue growth and profit margins, and a much lower future P/E, while also citing the recalibrated €9 Piper Sandler target following in-line Q3 revenue of €2.0m and early progress in the U.S. Genio launch. Analyst Commentary Recent research has highlighted a more cautious tone around Nyxoah, even as the U.S. Genio launch gets underway and Q3 revenue of €2.0m aligned with expectations.Narrative Update • Dec 26
NYXH: U.S. Reimbursement Progress Will Drive Constructive Long Term Upside
Analysts have moderately reduced their outlook on Nyxoah, trimming the average price target from $12 to $9. They are factoring in steady but measured progress of the U.S. Genio launch, in-line Q3 revenue of EUR 2.0M, and what they view as appropriately calibrated Q4 guidance of EUR 3.4M to EUR 3.6M amid a still demanding reimbursement approval process.Narrative Update • Dec 12
NYXH: U.S. Launch Execution Will Drive Constructive Long Term Upside
Analysts have lowered their price target on Nyxoah from approximately $18.60 to $13.00, citing a modestly higher discount rate, more conservative growth assumptions despite a stronger projected profit margin, and early but measured progress in the U.S. Genio launch that supports a reduced yet still constructive long term valuation multiple. Analyst Commentary Bullish analysts continue to frame the recent price target reductions as a recalibration rather than a reversal, emphasizing that the long term thesis around Nyxoah's U.S. opportunity and expanding commercial footprint remains intact.Narrative Update • Nov 27
NYXH: U.S. Launch Progress Will Drive Momentum Amid Approval Challenges
Analysts have lowered their price target for Nyxoah from $12.30 to $10.00, citing a cautious recalibration of future expectations. This comes despite steady revenue growth and progress with the U.S. Genio launch.
New Narrative • Apr 06
FDA Approval Will Launch Genio And Expand Global Reach
Imminent FDA approval of Genio could significantly boost revenues and market penetration in the U.S., driven by robust clinical results and strategic recruitment.Analysis Article • Jun 05
It's Probably Less Likely That Nyxoah S.A.'s (EBR:NYXH) CEO Will See A Huge Pay Rise This Year
Key Insights Nyxoah will host its Annual General Meeting on 12th of June Total pay for CEO Olivier Taelman includes...Analysis Article • Jan 24
Rock star Growth Puts Nyxoah (EBR:NYXH) In A Position To Use Debt
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Shareholder Returns
| NYXH | BE Medical Equipment | BE Market | |
|---|---|---|---|
| 7D | -5.7% | -0.9% | -2.2% |
| 1Y | -77.6% | -20.1% | 22.7% |
Return vs Industry: NYXH underperformed the Belgian Medical Equipment industry which returned -20.1% over the past year.
Return vs Market: NYXH underperformed the Belgian Market which returned 22.7% over the past year.
Price Volatility
| NYXH volatility | |
|---|---|
| NYXH Average Weekly Movement | 15.3% |
| Medical Equipment Industry Average Movement | 6.4% |
| Market Average Movement | 3.8% |
| 10% most volatile stocks in BE Market | 7.1% |
| 10% least volatile stocks in BE Market | 2.2% |
Stable Share Price: NYXH's share price has been volatile over the past 3 months compared to the Belgian market.
Volatility Over Time: NYXH's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of Belgian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 154 | Olivier Taelman | www.nyxoah.com |
Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat obstructive sleep apnea. Its lead solution is the Genio system, a hypoglossal neurostimulations therapy for obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
Nyxoah SA Fundamentals Summary
| NYXH fundamental statistics | |
|---|---|
| Market cap | €151.49m |
| Earnings (TTM) | -€83.64m |
| Revenue (TTM) | €15.33m |
9.7x
P/S Ratio-1.8x
P/E RatioIs NYXH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NYXH income statement (TTM) | |
|---|---|
| Revenue | €15.33m |
| Cost of Revenue | €6.02m |
| Gross Profit | €9.31m |
| Other Expenses | €92.95m |
| Earnings | -€83.64m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
Aug 05, 2026
| Earnings per share (EPS) | -0.84 |
| Gross Margin | 60.71% |
| Net Profit Margin | -545.70% |
| Debt/Equity Ratio | 94.5% |
How did NYXH perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/13 18:00 |
| End of Day Share Price | 2026/07/13 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Nyxoah SA is covered by 11 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Rescott | Baird |
| Michael Polark | Baird |
| Steven Halper | Cantor Fitzgerald & Co. |